CA2512043A1 - Use of n-desmethylclozapine to treat human neuropsychiatric disease - Google Patents

Use of n-desmethylclozapine to treat human neuropsychiatric disease Download PDF

Info

Publication number
CA2512043A1
CA2512043A1 CA002512043A CA2512043A CA2512043A1 CA 2512043 A1 CA2512043 A1 CA 2512043A1 CA 002512043 A CA002512043 A CA 002512043A CA 2512043 A CA2512043 A CA 2512043A CA 2512043 A1 CA2512043 A1 CA 2512043A1
Authority
CA
Canada
Prior art keywords
desmethylclozapine
subject
therapeutic agent
additional therapeutic
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002512043A
Other languages
English (en)
French (fr)
Inventor
David M. Weiner
Mark R. Brann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acadia Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2512043A1 publication Critical patent/CA2512043A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002512043A 2003-01-23 2004-01-21 Use of n-desmethylclozapine to treat human neuropsychiatric disease Abandoned CA2512043A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44269003P 2003-01-23 2003-01-23
US60/442,690 2003-01-23
PCT/US2004/001509 WO2004064753A2 (en) 2003-01-23 2004-01-21 Use of n-desmethylclozapine to treat human neuropsychiatric disease

Publications (1)

Publication Number Publication Date
CA2512043A1 true CA2512043A1 (en) 2004-08-05

Family

ID=32772052

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002512043A Abandoned CA2512043A1 (en) 2003-01-23 2004-01-21 Use of n-desmethylclozapine to treat human neuropsychiatric disease

Country Status (14)

Country Link
US (2) US20040224942A1 (enExample)
EP (2) EP1589974A2 (enExample)
JP (1) JP2006515628A (enExample)
KR (1) KR20050092123A (enExample)
CN (1) CN1741803A (enExample)
AU (1) AU2004206931A1 (enExample)
BR (1) BRPI0406592A (enExample)
CA (1) CA2512043A1 (enExample)
MX (1) MXPA05007784A (enExample)
NZ (1) NZ541014A (enExample)
RU (2) RU2336879C2 (enExample)
SG (1) SG159390A1 (enExample)
WO (1) WO2004064753A2 (enExample)
ZA (1) ZA200505878B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2397981C (en) 2000-03-06 2010-12-21 Acadia Pharmaceuticals, Inc. Azacyclic compounds for use in the treatment of serotonin related diseases
ATE466014T1 (de) 2001-12-28 2010-05-15 Acadia Pharm Inc Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
MXPA04012893A (es) 2002-06-24 2005-03-31 Acadia Pharm Inc Derivados de piperidina n-substituidos como agentes receptores de serotonina.
US7601740B2 (en) 2003-01-16 2009-10-13 Acadia Pharmaceuticals, Inc. Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
EP1589974A2 (en) * 2003-01-23 2005-11-02 Acadia Pharmaceuticals Inc. Use of n-desmethylclozapine to treat human neuropsychiatric disease
EP1596867A4 (en) * 2003-02-19 2006-03-22 Merck & Co Inc TREATMENT OF PSYCHOSIS WITH A MUSCARIN M1 RECEPTOR ECTOPIC ACTIVATOR
US20060217365A1 (en) * 2003-07-02 2006-09-28 Astrazeneca Ab Method of treating mood disorders
US20060252743A1 (en) * 2005-01-07 2006-11-09 Astrazeneca Ab Method of treating sleep disorders
US20070117789A1 (en) * 2005-11-18 2007-05-24 Astrazeneca Ab Method of treatment
US20090093461A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Methods of Treating Anxiety and Mood Disorders
US20060229292A1 (en) * 2005-01-07 2006-10-12 Astrazeneca Ab Method of treating childhood disorders
DE602004028739D1 (de) * 2003-07-02 2010-09-30 Astrazeneca Ab Metabolit von quetiapine
US20090093460A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Compositions
US20060217366A1 (en) * 2003-07-02 2006-09-28 Astrazeneca Ab Method of treating schizophrenia and other disorders
US20060217367A1 (en) * 2004-07-01 2006-09-28 Astrazeneca Ab Method of treating anxiety disorders
US20090239840A1 (en) * 2003-12-22 2009-09-24 Acadia Pharmaceuticals, Inc. AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS
PL1696931T3 (pl) 2003-12-22 2009-10-30 Acadia Pharm Inc Aminopodstawione analogi diarylo[A,D]cykloheptenowe jako agoniści receptorów muskarynowych i sposoby leczenia chorób neuropsychiatrycznych
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
RU2006138497A (ru) * 2004-04-01 2008-05-10 Акадиа Фармасьютикалз Инк. (Us) Кристаллические формы n-десметилклозапина
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US20050261278A1 (en) * 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
JP2008509147A (ja) * 2004-08-05 2008-03-27 アカディア ファーマシューティカルズ，インコーポレーテッド ヒト神経精神病を治療するためのｎ−デスメチルクロザピンの使用
DK1794126T3 (da) * 2004-09-27 2013-06-24 Acadia Pharm Inc Krystallinsk form af N-(-4-fluorbenzyl)-N-(1-methylpiperidn-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamid-hemitartrat
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
EP1865962A2 (en) * 2005-04-04 2007-12-19 Arcadia Pharmaceuticals Inc. Use of n-desmethylclozapine and related compounds as dopamine stabilizing agents
CA2620333A1 (en) * 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US20070105836A1 (en) * 2005-10-31 2007-05-10 Lars Pettersson Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
WO2007148341A2 (en) 2006-06-22 2007-12-27 Ramot At Tel Aviv University Ltd. Novel serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity
US9278947B2 (en) 2006-06-22 2016-03-08 Ramot At Tel-Aviv University Ltd. Serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity
ES2423485T3 (es) 2007-03-19 2013-09-20 Acadia Pharmaceuticals Inc. Asociaciones de agonistas y antagonistas inversos 5-HT2A con antipsicóticos
PL2307389T3 (pl) * 2008-06-20 2013-05-31 Astrazeneca Ab Pochodne dibenzotiazepiny i ich zastosowanie
US9018202B2 (en) * 2010-12-03 2015-04-28 Allergan, Inc. Methods for treating diseases of the retina
RU2506073C1 (ru) * 2012-09-06 2014-02-10 Алексей Николаевич Паршин Способ лечения расстройства адаптации у пациентов с суицидальным риском
US20160184290A1 (en) * 2014-12-31 2016-06-30 Paul J. Markovitz Method of treating schizophrenia
ES2890492T3 (es) 2015-07-20 2022-01-20 Acadia Pharm Inc Métodos para preparar N-(4-fluorobencil)-N-(1-metilpiperidin-4-il)-N'-(4-(2-metilpropiloxi)fenilmetil)carbamida y su sal de tartrato y forma polimórfica C
WO2017117347A1 (en) * 2015-12-30 2017-07-06 Markovitz M D Paul Method of treating schizophrenia
RU2667954C2 (ru) * 2016-03-04 2018-09-25 Общество С Ограниченной Ответственностью "Валентек" Фармацевтическая композиция для лечения функциональных психических расстройств
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2018118626A1 (en) 2016-12-20 2018-06-28 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
EP3615028A1 (en) 2017-04-28 2020-03-04 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
EP3675827A1 (en) 2017-08-30 2020-07-08 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN107970243B (zh) * 2017-10-30 2020-07-28 江苏理工学院 一种去甲氯氮平的新用途
CN109761826B (zh) * 2019-01-17 2022-02-25 烟台大学 一种o-去甲基文拉法辛苯醚化合物及其制备方法和用途
CN113993523A (zh) 2019-04-17 2022-01-28 指南针探路者有限公司 用赛洛西宾治疗抑郁症和其他各种病症

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL140242B (nl) * 1963-03-01 1973-11-15 Wander Ag Dr A Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen.
US3389139A (en) * 1963-06-14 1968-06-18 Wander Ag Dr A 6-homopiperazino and piperazinomorphanthridines
US3908010A (en) * 1967-03-22 1975-09-23 Wander Ag Dr A Basically substituted heterocycles as anti-emetics
US3884920A (en) * 1967-07-14 1975-05-20 Sandoz Ag 11-Basically substituted dibenz {8 b,f{9 {0 {8 1,4{9 {0 oxazepines
US3412193A (en) * 1965-12-13 1968-11-19 American Cyanamid Co 11-(4-methyl-1-piperazinyl)dibenz[b, f][1, 4]oxazepines or thiazepines for controlling fertility
AT278805B (de) * 1966-01-17 1970-02-10 American Cyanamid Co Verfahren zur herstellung von oxazepinen und thiazepinen
GB1184251A (en) * 1966-04-15 1970-03-11 American Cyanamid Co Oxazepines and Thiazepines
GB1192812A (en) * 1966-05-20 1970-05-20 American Cyanamid Co 2-Chloro-11-(1-Piperazinyl)Dibenz[b,f]-[1,4]Oxazepine, Non-Toxic Acid Addition Salts thereof, and Therapeutic Compositions containing said Oxazepine or Salts
US3852446A (en) * 1967-03-13 1974-12-03 Sandoz Ag Organic compounds in treatment of psychotic disturbances
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3751415A (en) * 1967-03-22 1973-08-07 Sandoz Ag 2-nitro-11-(1-piperazinyl)-dibenz(b,f)(1,4)oxazepines
US3758479A (en) * 1967-03-22 1973-09-11 Sandoz Ag Nitro and sulphamoyl substituted dibenzodiazepines
CA918659A (en) * 1969-07-31 1973-01-09 Yoshitomi Pharmaceutical Industries 11-(4-substituted-1-piperazinyl)-dibenzo (b,f) (1,4) thiazepines
US3660406A (en) * 1970-10-26 1972-05-02 American Cyanamid Co 2-chloro-7-hydroxy-11-(1-piperazinyl)dibenz(b f)(1 4)oxazepines
CH555856A (de) * 1971-05-04 1974-11-15 Hoffmann La Roche Verfahren zur herstellung von tricyclischen verbindungen.
US3962248A (en) * 1972-04-04 1976-06-08 Sandoz, Inc. Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines
US3884446A (en) * 1973-12-10 1975-05-20 Dahl Co G W Low profile control valve actuator
US3983234A (en) * 1974-07-04 1976-09-28 Sandoz Ltd. Treatment of dyskinesias
FI762646A7 (enExample) * 1975-09-24 1977-03-25 Sandoz Ag
US4045445A (en) * 1975-12-14 1977-08-30 American Cyanamid Company 11-(4-Piperidyl)dibenzo-diazepines
US4406900A (en) * 1976-11-10 1983-09-27 Sandoz Ltd. Neuroleptic use of morphanthridines
CH624682A5 (enExample) * 1976-11-10 1981-08-14 Sandoz Ag
US4191760A (en) * 1977-02-23 1980-03-04 Abbott Laboratories Dibenzodiazepines
US4097597A (en) * 1977-02-23 1978-06-27 Abbott Laboratories Dibenzo b,e! 1,4!diazepines
US4096261A (en) * 1977-02-23 1978-06-20 Abbott Laboratories Dibenzodiazepines
CS196893B1 (en) * 1977-12-22 1980-04-30 Miroslav Protiva 3-fluor-10-piperazino-8-substituted 10,11-dihydro-dibenzothiepines
US4263207A (en) * 1978-08-01 1981-04-21 Merck & Co., Inc. 10,11-Dihydrodibenzo[b,f][1,4]thiazepine carboxylic acids esters and amides thereof
US4268207A (en) * 1979-07-06 1981-05-19 Eaton Corporation Load support and shuttle
US4404137A (en) * 1979-10-16 1983-09-13 Lilly Industries Limited Pyrazolo [3,4-b][1,5]benzodiazepine compounds
CH641876A5 (de) * 1980-02-14 1984-03-15 Sulzer Ag Kolbenkompressor, insbesondere zum verdichten von sauerstoff.
US4663453A (en) * 1983-05-18 1987-05-05 Hoechst-Roussel Pharmaceuticals Inc. Benzo[b]pyrrolo[3,2,1-jk][1,4]benzodiazepines having dopamine receptor activity
US4764616A (en) * 1983-05-18 1988-08-16 Hoechst-Roussel Pharmaceuticals Inc. Benzopyrrolobenzodiazepines and quinobenzodiazepines
JPH04211071A (ja) * 1990-03-05 1992-08-03 Hokuriku Seiyaku Co Ltd 多環式化合物
US5817655A (en) * 1991-04-23 1998-10-06 Eli Lilly And Company Methods of treatment using a thieno-benzodiazepine
US5300422A (en) * 1991-12-04 1994-04-05 Case Western Reserve University Screening method for controlling agranulocytosis
US5393752A (en) * 1992-05-26 1995-02-28 Therabel Research S.A./N.V. Methylpiperazinoazepine compounds, preparation and use thereof
US5962664A (en) * 1993-05-13 1999-10-05 Friedhoff; Arnold J. Psychosis protecting nucleic acid, peptides, compositions and method of use
US5354747A (en) * 1993-06-16 1994-10-11 G. D. Searle & Co. 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use
IL110298A (en) 1993-07-13 1999-04-11 Brann Mark Robert Identification of ligands by selective amplification of cells transfected with receptors
US5538965A (en) * 1993-12-23 1996-07-23 Allelix Biopharmaceuticals Inc. Dopamine receptor ligands
US6566065B1 (en) * 1994-05-26 2003-05-20 Mcgill University Method of diagnosing schizophrenia by detecting a mutation in the (MTHFR) gene
US5700445A (en) * 1994-12-12 1997-12-23 Allelix Biopharmaceuticals, Inc. N-methyl piperazine compounds having dopamine receptor affinity
US5602124A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. 5-HT2 receptor ligands
US5602121A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. Alkyl-substituted compounds having dopamine receptor affinity
US5602120A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. Benzyl-substituted compounds having dopamine receptor affinity
GB9617305D0 (en) * 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
NZ521978A (en) * 2000-04-28 2004-10-29 Acadia Pharm Inc Compounds that affect cholinergic receptors and are particularly muscarinic agonists
RU2195957C2 (ru) * 2000-11-17 2003-01-10 Московский научно-исследовательский институт психиатрии Способ лечения негативных расстройств при шизофрении
WO2002060870A2 (en) * 2000-11-17 2002-08-08 Adolor Corporation Delta agonist analgesics
CN1681388A (zh) * 2002-09-18 2005-10-12 Fmc有限公司 三环衍生物杀虫剂
BR0317528A (pt) * 2002-12-20 2005-11-22 Basf Ag Uso dos compostos, métodos para o controle de insetos, aracnìdeos ou nematodos, e para a proteção de plantas em crescimento contra o ataque ou a infestação por insetos, aracnìdeos ou nematodos, compostos, e, composições
US7601740B2 (en) * 2003-01-16 2009-10-13 Acadia Pharmaceuticals, Inc. Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
EP1589974A2 (en) * 2003-01-23 2005-11-02 Acadia Pharmaceuticals Inc. Use of n-desmethylclozapine to treat human neuropsychiatric disease
US20070275957A1 (en) * 2003-01-23 2007-11-29 Weiner David M Use of n-desmethylclozapine to treat human neuropsychiatric disease
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
EP1596867A4 (en) * 2003-02-19 2006-03-22 Merck & Co Inc TREATMENT OF PSYCHOSIS WITH A MUSCARIN M1 RECEPTOR ECTOPIC ACTIVATOR
PL1696931T3 (pl) * 2003-12-22 2009-10-30 Acadia Pharm Inc Aminopodstawione analogi diarylo[A,D]cykloheptenowe jako agoniści receptorów muskarynowych i sposoby leczenia chorób neuropsychiatrycznych
RU2006138497A (ru) * 2004-04-01 2008-05-10 Акадиа Фармасьютикалз Инк. (Us) Кристаллические формы n-десметилклозапина
ES2378452T3 (es) * 2004-09-21 2012-04-12 Hypnion, Inc. �?cido 3-[4-(dibenzo[b,f][1,4]oxazepin-11-il)-piperazin-1-il]-2,2¿dimetil-propanoico para usarlo en el tratamiento de trastornos del sueño
US20060063754A1 (en) * 2004-09-21 2006-03-23 Edgar Dale M Methods of treating a sleep disorder
EP1865962A2 (en) * 2005-04-04 2007-12-19 Arcadia Pharmaceuticals Inc. Use of n-desmethylclozapine and related compounds as dopamine stabilizing agents
US20070105836A1 (en) * 2005-10-31 2007-05-10 Lars Pettersson Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders

Also Published As

Publication number Publication date
NZ541014A (en) 2008-05-30
WO2004064753A3 (en) 2004-11-25
US20090018119A1 (en) 2009-01-15
CN1741803A (zh) 2006-03-01
RU2008116931A (ru) 2009-11-10
US20040224942A1 (en) 2004-11-11
AU2004206931A1 (en) 2004-08-05
SG159390A1 (en) 2010-03-30
EP1589974A2 (en) 2005-11-02
EP1994932A1 (en) 2008-11-26
RU2336879C2 (ru) 2008-10-27
JP2006515628A (ja) 2006-06-01
BRPI0406592A (pt) 2005-12-20
WO2004064753A2 (en) 2004-08-05
KR20050092123A (ko) 2005-09-20
MXPA05007784A (es) 2005-09-30
RU2005126614A (ru) 2006-01-27
ZA200505878B (en) 2006-04-26

Similar Documents

Publication Publication Date Title
RU2336879C2 (ru) Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей
Baldessarini et al. Pharmacotherapy of psychosis and mania
US20060199807A1 (en) Use of N-desmethylclozapine to treat human neuropsychia tric disease
US20050085463A1 (en) Use of N-desmethylclozapine to treat human neuropsychiatric disease
US5945416A (en) Method for treating pain
US20070275957A1 (en) Use of n-desmethylclozapine to treat human neuropsychiatric disease
US20060276412A1 (en) Methods and compositions for managing psychotic disorders
EP2288345A1 (en) Psycho-pharmaceuticals
CN101128198A (zh) 沙贝马啉与安定药物联合治疗精神病
KR20040027892A (ko) 편두통의 치료를 위한 기타 항편두통 약물과의 배합물에서βⅰβν4096의 용도
WO2006017614A1 (en) Use of n-desmethylclozapine to treat human neuropsychiatric disease
US20080096870A1 (en) Methods and Materials for Treating Mental Illness
Grunze et al. Combined treatment with lithium and nimodipine in a bipolar I manic syndrome
NZ519381A (en) New therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
WO2008002602A1 (en) Use of n-desmethylclozapine to treat psychosis
US20250205200A1 (en) 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression
CN101094674A (zh) N－去甲基氯氮平治疗人神经精神疾病的用途
US20250221963A1 (en) 5-meo-dmt for use in the treatment of postpartum depression
HK1116664A (en) Use of n-desmethylclozapine to treat human neuropsychiatric disease
HK1088839A (en) Use of n-desmethylclozapine to treat human neuropsychiatric disease
CA2617420A1 (en) Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued